NHS FPX 6004 Assessment 1 Dashboard Metrics Evaluation
Student Name Capella University NHS-FPX 6004 Health Care Law and Policy Prof. Name Date Dashboard Metrics Evaluation Introduction to Dashboard Metrics Evaluation Healthcare organizations commonly utilize performance dashboards to track clinical outcomes and operational performance. These dashboards transform raw data into visual metrics that allow organizations to compare their performance against benchmarks established by national or regional healthcare authorities. According to Helminski et al. (2022), dashboard analytics enable healthcare teams to quickly identify performance trends and areas that require improvement. The present dashboard evaluation focuses on diabetes management indicators at Mercy Medical Center (MMC). Specifically, it examines three critical clinical metrics used to monitor diabetes care: Hemoglobin A1c (HgbA1c) testing, annual eye examinations, and foot examinations. These indicators are widely recognized as essential measures for preventing complications associated with diabetes. By analyzing these dashboard metrics, healthcare leaders can detect performance gaps and implement targeted strategies to strengthen diabetes management practices within the organization. Evaluation of Dashboard Metrics Healthcare agencies have established evidence-based benchmarks to guide effective diabetes monitoring and management. The American Diabetes Association (ADA) recommends that individuals with diabetes receive routine HgbA1c testing as well as annual eye and foot examinations to detect complications at an early stage (Cooksey, 2020). Similarly, the National Healthcare Quality and Disparities Report (NHQDR) recommends that patients undergo at least two HgbA1c tests annually, with a performance benchmark of approximately 79.5% compliance (ADA, 2019). The Vila Health Dashboard provides performance data for the years 2019 and 2020, organized by four quarterly reporting periods. A detailed review of the data indicates that MMC is experiencing declining performance in certain metrics, particularly HgbA1c testing and foot examination rates. For example, in the third quarter (Q3) of 2020, 78 patients completed HgbA1c testing; however, this number declined to 64 patients in the fourth quarter (Q4). Such a downward trend suggests reduced screening compliance compared with recommended benchmarks. Foot examination data reveal even greater inconsistencies across the reporting periods. The recorded values for 2020 were 75 patients in Q1, 50 patients in Q2, 48 patients in Q3, and 62 patients in Q4. Although the fourth quarter shows a slight improvement, the overall numbers remain significantly below optimal screening levels. The importance of routine foot examinations cannot be overstated. Annual foot assessments allow clinicians to detect early signs of neuropathy, infection, or vascular complications. When these examinations are delayed or omitted, patients with diabetes may experience reduced sensation, increased susceptibility to wounds, delayed wound healing, and in severe cases, lower limb amputation (Song & Chambers, 2021). These complications not only reduce patients’ quality of life but also increase healthcare costs due to hospitalization and long-term care. Similarly, HgbA1c testing is a critical clinical measure that evaluates long-term blood glucose control. It provides an overview of average glucose levels over the previous two to three months and helps clinicians determine whether diabetes is being effectively managed. Several healthcare policies, including those issued by the Centers for Medicare and Medicaid Services (CMS), emphasize preventive screening and routine monitoring of HgbA1c levels as essential components of diabetes care (CMS, 2023). Consequently, MMC must improve both its HgbA1c testing rates and foot examination compliance in order to align with established healthcare standards. Summary of Key Dashboard Metrics Metric Benchmark Recommendation MMC Observed Trend Key Concern HgbA1c Testing At least 2 tests per year; benchmark ≈ 79.5% Decline from 78 (Q3 2020) to 64 (Q4 2020) Below national benchmark Eye Examination At least once per year Data available but not emphasized in dashboard analysis Requires continued monitoring Foot Examination Annual examination recommended Fluctuations: 75 → 50 → 48 → 62 (2020) Inconsistent screening rates Organizational Performance Shortfalls and Informational Gaps The dashboard provides demographic information for newly registered patients, including race, gender, and age distribution. However, it does not include data on returning patients or individuals who were evaluated in earlier quarters. This absence of longitudinal data limits the ability to identify patterns in patient outcomes or to measure continuity of care. Available demographic information indicates that White patients represent the largest group receiving services (63%). Additionally, female patients account for approximately 62% of the population served, while male patients represent 38%. Regarding age distribution, individuals between 40 and 64 years constitute the largest proportion (38%) undergoing diabetes-related tests. Although these statistics provide a general demographic overview, the dashboard lacks sufficient detail to fully evaluate disparities in healthcare delivery. For example, it does not indicate whether certain racial or socioeconomic groups experience lower screening rates or poorer health outcomes. Moreover, the data do not explain the underlying causes behind reduced HgbA1c testing and foot examination rates. Another significant observation involves the organization’s performance gap in meeting benchmark targets. The data show that HgbA1c compliance improved slightly from 37% in 2019 to 48% in 2020. While this increase represents progress, it remains far below the benchmark recommended by national quality organizations (ADA, 2019). To close this gap, MMC must significantly increase its screening rates and improve care coordination. Consequences of Not Meeting Prescribed Benchmarks Failure to meet established diabetes management benchmarks can have significant consequences for patients, healthcare professionals, and the healthcare organization. One major impact is the deterioration in the quality of patient care. When essential screenings such as foot, eye, or HgbA1c tests are delayed or omitted, early detection of complications becomes unlikely. As a result, patients may experience irreversible damage to organs such as the eyes or lower limbs, leading to long-term disability or chronic disease progression (Lv et al., 2023). Patient satisfaction may also decline when recommended screenings are not consistently performed. Patients often expect healthcare providers to deliver preventive care and timely monitoring. When healthcare systems fail to meet these expectations, trust in the organization may diminish. From an organizational perspective, failing to meet national quality benchmarks can also result in financial and legal consequences. Healthcare organizations operating under value-based reimbursement models may face reduced reimbursement rates or financial penalties when quality indicators are not met (Jing et al., 2023). Additionally, public reporting of healthcare quality metrics can affect